Diabetes/Alzheimer's Biotech Vitae Pharmaceuticals, Inc. Sets Terms For $60 Million IPO

Published: Sep 09, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Vitae Pharmaceuticals, which uses software to develop small molecule drugs for type 2 diabetes and Alzheimer's, announced terms for its IPO on Monday. The Fort Washington, PA-based company plans to raise $60 million by offering 5.0 million shares at a price range of $11 to $13. Insiders intend to purchase $11 million worth of shares on the offering (18% of the deal). At the midpoint of the proposed range, Vitae Pharmaceuticals would command a fully diluted market value of $198 million.

Help employers find you! Check out all the jobs and post your resume.

Back to news